Conversion to a Belatacept Based Immunosuppression Regimen in Renal Transplant Recipients

被引：0
|
作者：
Paplaczyk, K. [1 ]
Cunningham, K. [1 ]
D'Agostino, C. [1 ]
Pinelli, D. [1 ]
Schulte, J. [1 ]
Shetty, A. [1 ]
机构：
[1] Northwestern Mem Hosp, Chicago, IL 60611 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2020年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
116
引用
收藏
页码：439 / 440
页数：2
相关论文
共 50 条
  • [31] Renal Function Outcomes in Kidney Transplant Recipients After Conversion to Everolimus-Based Immunosuppression Regimen with CNI Reduction or Elimination
    Cataneo-Davila, A.
    Zuniga-Varga, J.
    Correa-Rotter, R.
    Alberu, J.
    TRANSPLANTATION PROCEEDINGS, 2009, 41 (10) : 4138 - 4146
  • [32] Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction
    Snyder, Heather S.
    Duhart, Benjamin T., Jr.
    Krauss, Amy G.
    Rao, Vinaya
    SAGE OPEN MEDICAL CASE REPORTS, 2016, 4
  • [33] Belatacept-versus Cyclosporine-Based Immunosuppression in Renal Transplant Recipients with Pre-existing Diabetes
    Rostaing, Lionel
    Neumayer, Hans H.
    Reyes-Acevedo, Rafael
    Bresnahan, Barbara
    Florman, Sander
    Vitko, Stefan
    Heifets, Michael
    Xing, Jun
    Thomas, Dolca
    Vincenti, Flavio
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (11): : 2696 - 2704
  • [34] Cost Effectiveness of a Belatacept-Based Regimen in Kidney Transplant Recipients.
    Caccioppoli, V.
    MacLasco, A.
    Chan, K.
    Gandhi, R.
    LaBella, S.
    Somers, L.
    Rogers, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 183 - 183
  • [35] Impact of Belatacept Conversion on Renal Function and Donor Specific Antibodies in Renal Transplant Recipients.
    Brown, E. R.
    Cunningham, K.
    Paplaczyk, K.
    Dagostino, C.
    Kane, C.
    Shetty, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 710 - 711
  • [36] Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients
    Sethi, Supreet
    Najjar, Reiad
    Peng, Alice
    Choi, Jua
    Lim, Kathlyn
    Vo, Ashley
    Jordan, Stanley C.
    Huang, Edmund
    TRANSPLANTATION, 2020, 104 (07) : 1500 - 1507
  • [37] BELATACEPT USE IN COMPLEX RENAL TRANSPLANT RECIPIENTS
    Teng, Chui Ling
    Dukka, Hari
    Rathore, Roshni
    Tomlinson, Kerry
    Daga, Sunil
    Halawa, Ahmed
    TRANSPLANT INTERNATIONAL, 2017, 30 : 487 - 487
  • [38] Utilization of Belatacept in Renal Transplant Recipients in USA
    Wen, Xuerong
    Womer, Karl L.
    Casey, Michael J.
    Santos, Alsonso H.
    Hartzema, Abraham G.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 601 - 601
  • [39] Conversion to rapamycin immunosuppression in renal transplant recipients: Report of an initial experience
    Dominguez, J
    Mahalati, K
    Kiberd, B
    McAlister, VC
    MacDonald, AS
    TRANSPLANTATION, 2000, 70 (08) : 1244 - 1247
  • [40] A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)
    Vincenti, F.
    Charpentier, B.
    Vanrenterghem, Y.
    Rostaing, L.
    Bresnahan, B.
    Darji, P.
    Massari, P.
    Mondragon-Ramirez, G. A.
    Agarwal, M.
    Di Russo, G.
    Lin, C. -S.
    Garg, P.
    Larsen, C. P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (03) : 535 - 546
12345